Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 04, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding share transactions and does not contain financial performance data.
Material Changes
The filing details specific share movements within the SmithKline Beecham Employee Benefit Trust ("the Trust") on December 1, 2006:
- Share Sales: 705 Ordinary shares were sold on behalf of participants in the SmithKline Beecham Bonus Investment Plan at a price of GBP13.61 per share.
- Share Transfers: 1,010 Ordinary shares were transferred from the Trust to a participant in the same plan.
Director Mr. J S Heslop is noted as having an interest in the shares held in the fund, consistent with other non-US employees and former employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the specific transactions described above in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total volume of shares sold (705) and transferred (1,010) within the SmithKline Beecham Employee Benefit Trust.
- Confirm the transaction price of GBP13.61 per share for the sold units.
- Review the role of the Trust as a discretionary fund for non-US employees and former employees.
- Note that Director Mr. J S Heslop's interest is derived from his status as a potential beneficiary of the Trust, not direct ownership of the specific shares traded.